

# Balance Sheet

as at March 31, 2024

₹ in Million			
Particulars	Notes	As at March 31, 2024	As at March 31, 2023
<b>ASSETS</b>			
<b>(1) Non-current assets</b>			
(a) Property, plant and equipment	3A (I) & (II)	101,923.2	103,903.8
(b) Building	3D	11,077.3	9,633.5
(c) Goodwill	47	85,989.5	83,580.3
(d) Patents for drugs and formulations	3B	33,201.1	33,170.3
(e) Intangible assets under development (R&D)	3E	64,461.5	60,098.1
(f) Investment in associates	4	4,061.3	3,474.8
(g) Investment in joint venture	5	364.8	361.6
(h) Financial assets			
(i) Investments	6	59,986.2	50,680.9
(ii) Loans	7	8.5	6.1
(iii) Other financial assets	8	1,179.5	1,710.4
(i) Deferred tax assets (Net)	50	41,036.5	35,189.2
(j) Income tax assets (Net)	9	22,850.3	23,069.8
(k) Other non-current assets	10	4,739.3	3,723.7
<b>Total non-current assets</b>		<b>419,879.0</b>	<b>408,602.5</b>
<b>(2) Current assets</b>			
(a) Inventories	11	98,682.9	105,130.5
(b) Financial assets			
(i) Investments	12	85,845.4	93,726.1
(ii) Trade receivables	13	112,493.7	114,385.1
(iii) Cash and cash equivalents	14	92,856.5	46,237.3
(iv) Bank balances other than (iii) above	15	12,350.3	11,465.6
(v) Loans	16	650.2	413.2
(vi) Other financial assets	17	9,172.0	7,645.1
(c) Other current assets	18	22,280.1	19,616.5
<b>Total current assets</b>		<b>434,331.1</b>	<b>398,619.4</b>
Assets classified as held for sale	3C	418.7	214.0
<b>TOTAL ASSETS</b>		<b>865,628.8</b>	<b>807,435.9</b>

# Balance Sheet

as at March 31, 2024

₹ in Million

Particulars	Notes	As at March 31, 2024	As at March 31, 2023
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
(a) Equity share capital	19	2,399.3	2,399.3
(b) Other equity	20	634,268.2	557,554.5
<b>Equity attributable to the equity shareholders of the parent company</b>		<b>636,667.5</b>	<b>559,953.8</b>
Non-controlling interests	71	34,392.2	33,200.9
<b>Total equity</b>		<b>671,059.7</b>	<b>593,154.7</b>
<b>Liabilities</b>			
<b>(1) Non-current liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	21	13.3	-
(ii) Lease liabilities	54	3,022.9	5,599.1
(iii) Other financial liabilities	22	-	37.9
(b) Provisions	23	4,138.9	3,429.1
(c) Deferred tax liabilities (Net)	50	1,550.6	316.9
(d) Other non-current liabilities	24	4,999.4	5,828.2
<b>Total non-current liabilities</b>		<b>13,725.1</b>	<b>15,211.2</b>
<b>(2) Current liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	25	39,443.6	61,978.8
(ii) Lease liabilities	54	1,256.9	1,280.8
(iii) Trade payables	74	56,533.0	56,815.2
(iv) Other financial liabilities	26	15,067.0	15,930.9
(b) Other current liabilities	27	10,844.6	6,427.2
(c) Provisions	28	53,575.6	53,543.8
(d) Current tax liabilities (Net)	29	4,117.0	3,087.1
<b>Total current liabilities</b>		<b>169,837.7</b>	<b>199,063.8</b>
Liabilities directly associated with assets classified as held for sale	3C	6.3	6.2
<b>Total liabilities</b>		<b>194,569.1</b>	<b>214,281.2</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>865,628.8</b>	<b>807,435.9</b>

The accompanying notes are an integral part of the financial statements.  
As per our report of even date

For **N B S B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 326482E/E346863

per **POUL ALWARES**

Partner

Membership No.: 1054

Mumbai, May 22, 2024

**ARUP PANDEY**

Company Secretary and Compliance Officer

For and on behalf of the Board of Directors of

**MOON PHARMACEUTICAL INDUSTRIES LIMITED**

**ARJUN VINOD**

Chairman and Managing Director

(DIN: 00004459)

**RAMESH JAIN**

Whole-time Director

(DIN: 01762734)

**RAHUL RAMESH**

Chief Financial Officer

Mumbai, May 22, 2024

# Statement of Profit and Loss

for the year ended March 31, 2024

₹ in Million

Particulars	Notes	Year ended March 31, 2024	Year ended March 31, 2023
(I) Revenue from operations	30	484,968.5	438,856.8
(II) Other income	31	13,541.9	6,345.2
<b>(III) Total income (I+II)</b>		<b>498,510.4</b>	<b>445,202.0</b>
<b>(IV) Expenses</b>			
Cost of materials consumed	32	69,043.3	77,775.7
Purchases of stock-in-trade		34,661.5	35,715.0
Changes in inventories of finished goods, stock-in-trade and work-in-progress	33	2,921.3	(6,869.1)
Employee benefits expense	34	94,290.6	82,960.3
Finance costs	35	2,384.7	1,720.0
Depreciation and amortisation expense	3 (A & B)	25,566.4	25,294.3
Other expenses	36	154,181.8	131,546.0
Net (gain) / loss on foreign currency transactions		(361.3)	1,261.0
<b>Total expenses (IV)</b>		<b>382,688.3</b>	<b>349,403.2</b>
<b>(V) Profit before exceptional items and tax (III-IV)</b>		<b>115,822.1</b>	<b>95,798.8</b>
(VI) Exceptional items	61	4,943.2	1,714.5
<b>(VII) Profit before tax (V-VI)</b>		<b>110,878.9</b>	<b>94,084.3</b>
<b>(VIII) Tax expense/(credit)</b>			
Current tax		19,893.0	18,692.2
Deferred tax		(5,498.5)	(10,216.3)
<b>Total tax expense (VIII)</b>	49	<b>14,394.5</b>	<b>8,475.9</b>
<b>(IX) Profit for the year before share of profit/(loss) of associates and joint venture (VII-VIII)</b>		<b>96,484.4</b>	<b>85,608.4</b>
(X) Share of profit/(loss) of associates (net of tax)		(382.7)	(476.7)
(XI) Share of profit/(loss) of joint venture (net of tax)		(1.4)	(2.3)
<b>(XII) Profit for the year before non-controlling interests (IX+X+XI)</b>		<b>96,100.3</b>	<b>85,129.4</b>
(XIII) Non-controlling interests	71	336.5	393.6
<b>(XIV) Profit for the year of the parent company (XII-XIII)</b>		<b>95,763.8</b>	<b>84,735.8</b>
<b>Earnings per equity share (face value per equity share - ₹ 1)</b>			
Basic		35.9	28.5
Diluted		35.9	28.5

The accompanying notes are an integral part of the financial statements.  
As per our report of even date

For **N B S B C & CO LLP**  
Chartered Accountants  
ICAI Firm Registration No.: 326482E/E346863

per **POUL ALWARES**  
Partner  
Membership No.: 1054  
Mumbai, May 22, 2024

**ARUP PANDEY**  
Company Secretary and Compliance Officer

For and on behalf of the Board of Directors of  
**MOON PHARMACEUTICAL INDUSTRIES LIMITED**

**ARJUN VINOD**  
Chairman and Managing Director  
(DIN: 00004459)

**RAMESH JAIN**  
Whole-time Director  
(DIN: 01762734)

**RAHUL RAMESH**  
Chief Financial Officer  
Mumbai, May 22, 2024

## NOTE: 3E Intangible assets under development (R&D)

Moon Pharmaceutical began the year with a robust investment in R&D totalling ₹60,098.1 million, representing a dedicated 15% of our total non-current assets, reflecting our strategic commitment to long-term innovation. During this fiscal year, we strategically increased our R&D investments by ₹4,363.4 million, approximately a 7.3% increase from the previous year. This investment is focused on the development of innovative drug therapies and advanced diagnostic tools that are projected to address unmet medical needs and capture new market segments. The capitalization of R&D costs allows us to align the expense recognition with the expected timing of benefits derived from these assets. This approach ensures that our financial statements reflect our operational reality and provide our investors with a clear view of how R&D contributes to value creation.

Below is a table showcasing the progression and key activities impacting the balance of R&D investments throughout the year: -

Activity	Amount (₹ in million)	Description
Opening Balance	60,098.1	Initial investment in ongoing R&D projects from the previous fiscal year.
New Investments	8,000.0	Additional funds are allocated to new and continuing R&D projects focussing on next-generation therapies.
Capitalization	(791.3)	Costs transferred from R&D to tangible assets upon completion of development phases, ready for commercialization.
Impairments	(1,561.1)	Write-downs reflecting adjustments to the carrying value of certain projects that did not proceed as expected.
Foreign Currency Translation	542.5	Gains due to favourable foreign exchange rate movements affect the valuation of international R&D projects.
Other Adjustments	(826.7)	Miscellaneous adjustments, including corrections, reclassifications, or minor disposals.
Closing Balance	64,461.5	The total value of R&D assets under development at the end of the fiscal year, prepared for future benefits.

### **Rationale for Capitalization:**

These R&D expenditures have been capitalized as they meet our stringent criteria for capitalization, which include:

- **Technical Feasibility:** Each project has demonstrated technical feasibility through successful Phase II clinical trials, confirming the potential for full regulatory approval and market entry.
- **Economic Viability:** Detailed market analyses predict that these projects could increase our market share by up to 10% in targeted segments, with expected revenue generation commencing within the next 3 years.
- **Future Economic Benefits:** The capitalized projects are expected to contribute significantly to our earnings, with a projected increase in EBITDA by approximately 22% over the next twenty years due to these innovations.